Clinical and economic evaluation of the use of favipiravir in treatment regimens for COVID-19

  • Authors: Krysanov I.S.1,2, Gurevich K.G.1, Matveeva N.V.3, Matveev A.V.4, Zaslavskaya K.Y.5, Krysanova V.S.2, Ermakova V.Y.6, Kurkin D.V.1, Balykova L.A.5, Belyi P.A.1, Zemskov D.N.5, Makarova E.V.1
  • Affiliations:
    1. Russian University of Medicine, Moscow, Russia
    2. Russian Biotechnological University, Moscow, Russia
    3. V. I. Vernadsky Crimean Federal University, Simferopol, Russia
    4. Russian Medical Academy of Continuing Professional Education, Moscow, Russia
    5. National Research Mordovian State University named after N. P. Ogarev, Saransk, Russia
    6. I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
  • Issue: No 2 (2024)
  • Pages: 109-119
  • Section: Articles
  • URL: https://remedium-journal.ru/journal/article/view/1707
  • DOI: https://doi.org/10.32687/1561-5936-2024-28-2-109-119
  • Cite item

Abstract


Background. Currently, sufficient information has been accumulated the literature on the clinical effectiveness and safety of favipiravir in adult patients with COVID-19, including cases of its use in intensive care units and in comorbid patients. This article summarizes the latest published data from clinical studies, systematic reviews and meta-analyses, including data from real-life clinical practice. A number of studies have conducted a pharmacoeconomic evaluation of the use of favipiravir in adult patients with COVID-19. Objective. To evaluate pharmacoeconomic efficacy of the use of favipiravir in adult patients with non-severe forms of COVID-19 in a Russian hospital settings. Materials and methods. On the basis of the clinic of the Russian University of Medicine a non-interventional clinical study was performed, including 201 patients with mild COVID-19. Patients were divided into two groups: with favipiravir therapy or without it. Results. A reduction in hospitalization time by 2 days was demonstrated in patients with COVID-19 receiving favipiravir, which leads to the reduction in hospitalization costs for 1 patient in the amount of RUB 16,643.69. Conclusions. Thus, various data on the use of favipiravir for COVID-19 allow us to demonstrate pharmacoeconomic benefits, both in terms of budgetary savings and a positive impact on reducing the burden on the healthcare system and improving key medical statistics, including morbidity and mortality.

About the authors

Ivan S. Krysanov

Russian University of Medicine, Moscow, Russia; Russian Biotechnological University, Moscow, Russia

Email: krysanov-ivan@mail.ru

Konstantin G. Gurevich

Russian University of Medicine, Moscow, Russia

Email: kgurevich@mail.ru

Natalia V. Matveeva

V. I. Vernadsky Crimean Federal University, Simferopol, Russia

Email: matveevanatasha@gmail.com

Alexander V. Matveev

Russian Medical Academy of Continuing Professional Education, Moscow, Russia

Email: avmcsmu@gmail.com

Kira Ya. Zaslavskaya

National Research Mordovian State University named after N. P. Ogarev, Saransk, Russia

Email: kiryonok@yandex.ru

Vera S. Krysanova

Russian Biotechnological University, Moscow, Russia

Email: krysanovavs@mgupp.ru

Victoria Yu. Ermakova

I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia

Email: ermakova.viktoriya.yurievna@mail.ru

Denis V. Kurkin

Russian University of Medicine, Moscow, Russia

Email: strannik986@mail.ru

Larisa A. Balykova

National Research Mordovian State University named after N. P. Ogarev, Saransk, Russia

Email: larisabalykova@yandex.ru

Petr A. Belyi

Russian University of Medicine, Moscow, Russia

Email: pbely@ncpharm.ru

Dmitry N. Zemskov

National Research Mordovian State University named after N. P. Ogarev, Saransk, Russia

Email: dizem1978@gmail.com

Ekaterina V. Makarova

Russian University of Medicine, Moscow, Russia

Email: rue-royal@inbox.ru

References

  1. Temporary guidelines. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19) 17th ed., Moscow, 2022. 260 p. (In Russ.)
  2. Furuta Y., Komeno T., Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc. Jpn Acad. Ser. B Phys. Biol. Sci. 2017;93(7):449–463. doi: 10.2183/pjab.93.027
  3. Shrestha D. B., Budhathoki P., Khadka S. et al. Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis. Virol. J. 2020;17(1):141. doi: 10.1186/s12985-020-01412-z
  4. Prakash A., Singh H., Kaur H. et al. Systematic review and meta-analysis of effectiveness and safety of favipiravir in the management of novel coronavirus (COVID-19) patients. Indian J. Pharmacol. 2020;52(5):414–421. doi: 10.4103/ijp.ijp_998_20
  5. Manabe T., Kambayashi D., Akatsu H., Kudo K. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis. BMC Infect. Dis. 2021;21(1):489. doi: 10.1186/s12879-021-06164-x
  6. Hassanipour S., Arab-Zozani M., Amani B. et al. The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. Sci. Rep. 2021;11(1):11022. doi: 10.1038/s41598-021-90551-6
  7. Özlüşen B., Kozan Ş., Akcan R. E. et al. Effectiveness of favipiravir in COVID-19: a live systematic review. Eur. J. Clin. Microbiol. Infect. Dis. 2021;40(12):2575–2583. doi: 10.1007/s10096-021-04307-1
  8. Qomara W. F., Primanissa D. N., Amalia S. H. et al. Effectiveness of Remdesivir, Lopinavir/Ritonavir, and Favipiravir for COVID-19 treatment: a systematic review. Int. J. Gen. Med. 2021;14:8557–8571. doi: 10.2147/IJGM.S332458
  9. Gil Martínez V., Avedillo Salas A., Santander Ballestín S. Antiviral therapeutic approaches for SARS-CoV-2 infection: a systematic review. Pharmaceuticals (Basel). 2021. Vol. 14(8):736. doi: 10.3390/ph14080736
  10. Udwadia Z. F., Singh P., Barkate H. et al. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: a randomized, comparative, open-label, multicenter, phase 3 clinical trial. Int. J. Infect. Dis. 2021;103:62–71. doi: 10.1016/j.ijid.2020.11.142
  11. Balykova L. A., Radaeva O. A., Zaslavskaya K. Y. et al. Study of clinical and pathogenetic effects of anti-viral drug based on favipiravir in comorbid patients with COVID-19 at the outpatient stage of treatment. Pharmacy & Pharmacology. 2021;9(6):454–464. (In Russ.) doi: 10.19163/2307-9266-2021-9-6-454-464
  12. Chen C., Zhang Y., Huang J. et al. Favipiravir versus Arbidol for clinical recovery rate in moderate and severe adult COVID-19 patients: a prospective, multicenter, open-label, randomized controlled clinical trial. Front Pharmacol. 2021;12:683296. doi: 10.3389/fphar.2021.683296
  13. Doi Y., Hibino M., Hase R. et al. A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19. Antimicrob. Agents Chemother. 2020;64(12):e01897–e01920. doi: 10.1128/AAC.01897-20
  14. Agrawal U., Raju R., Udwadia Z. F. Favipiravir: a new and emerging antiviral option in COVID-14. Med. J. Armed Forces India. 2020;76(4):370–376. doi: 10.1016/j.mjafi.2020.08.004
  15. Ivashchenko A. A., Dmitriev K. A., Vostokova N. V. et al. Avifavir for treatment of patients with moderate Coronavirus Disease 2019 (COVID-19): interim results of a phase II/III multicenter randomized clinical trial. Clin. Infect. Dis. 2021;73(3):531–534. doi: 10.1093/cid/ciaa1176
  16. Balykova L. A., Govorov A. V., Vasilyev A. O. et al. Characteristics of COVID-19 and possibilities of early causal therapy. Results of favipiravir use in clinical practice. Infectious diseases. 2020;18(3):30–40. (In Russ.) doi: 10.20953/1729-9225-2020-3-30-40
  17. Balykova L. A., Pavelkina V. F., Shmyreva N. V. et al. Efficacy and safety of some etiotropic therapeutic schemes for treating patients with novel coronavirus infection (COVID-19). Pharmacy & Pharmacology. 2020;8(3):150–159. (In Russ.) doi: 10.19163/2307-9266-2020-8-3-150-159
  18. Ruzhentsova T. A., Chukhliaev P. V., Khavkina D. A. et al. Potential for etiotropic therapy of SARSCoV-2-induced coronavirus disease in outpatients. Medical Opponent. 2020;1(9):48–58. In Russ.)
  19. Pilkington V., Pepperrell T., Hill A. A review of the safety of favipiravir — a potential treatment in the COVID-19 pandemic? J. Virus Erad. 2020;6(2):45–51. doi: 10.1016/S2055-6640(20)30016-9
  20. Kumagai Y., Murakawa Y., Hasunuma T. et al. Lack of effect of favipiravir, a novel antiviral agent, on QT interval in healthy Japanese adults. Int. J. Clin. Pharmacol. Ther. 2015;53(10):866–874. doi: 10.5414/CP202388
  21. Shiraki K., Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol. Ther. 2020;209:107512. doi: 10.1016/j.pharmthera.2020.107512

Statistics

Views

Abstract - 7

PDF (Russian) - 5

Cited-By


PlumX

Dimensions


Copyright (c) 2024 АО "Шико"

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Mailing Address

Address: 105064, Moscow, st. Vorontsovo Pole, 12, building 1

Email: redactor@remedium-journal.ru

Phone: +7(495) 917-48-86



Principal Contact

Sherstneva Elena Vladimirovna
EXECUTIVE SECRETARY
FSSBI «N.A. Semashko National Research Institute of Public Health»

105064, Vorontsovo Pole st., 12, Moscow


Email: redactor@remedium-journal.ru

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies